New eczema drug enters first human tests

NCT ID NCT07488065

Recruiting now Symptom relief Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goals are to check safety and how the body processes the drug. A small group of eczema patients will also be monitored for skin improvement. The study is still recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Huashan Hospital Affiliated to Fudan University
RECRUITING

Shanghai, 200040, China
Huashan Hospital Affiliated to Fudan University
RECRUITING

Shanghai, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.